It’s more fun to go to work because we have more options for our patients. Even more exciting is that our patients are more hopeful and more engaged in self-care and advocacy. It’s wonderful to have a new option that changes people’s lives.
-Jessica Ailani, MD, FAHS
Georgetown University, Washington, DC
I have new options for patients, which has improved treatment adherence and, although it may need to be done slowly, reduced polypharmacy for many. I hope this can be applied in the future to difficult posttraumatic migraines.
-Shae Datta, MD
University of Florida, Gainesville, FL
These treatments have changed my practice. I can now offer new options to people with cardiovascular or other comorbidities and polypharmacy that kept them from using previously available therapies.
-Rebecca Burch, MD
Brigham and Women’s Hospital, Harvard University, Boston, MA
These treatments have changed the way we think—from considering treatment of attacks to thinking about treating a disease process with significant associated disability. This has changed the conversation with our patients and brought great hope to many.
-Rashmi B. Halker Singh, MD, FAHS
Mayo Clinic, Scottsdale, AZ
It has given my patients more options, which is always a good thing.
-Melissa Rayhill, MD
University at Buffalo, SUNY, Buffalo, NY
It has been a year of tissues—many patients come back in tears, so happy to tell you that it worked. Some, however, come back in tears because it didn’t. We have to remember that there is more work to be done. Overall, it is bringing more people into the field because we are able to make a difference for more people now, which is what brought so many of us into medicine.
- Peter Goadsby, MD
King’s College, London, England
In pediatric practice, clinical trials and FDA-approval are not yet available. Many of us are collecting safety data from use in older adolescents and young adults. What I’ve seen, in general, is that these treatments are working well and bringing hope to children and families who haven’t had that for quite some time.
-Chris Oakley, MD
Johns Hopkins University, Baltimore, MD
We have more options, and the most exciting aspect, reflected at this meeting, is that these therapies, based on migraine science, show us what we are capable of as a field.
-Andrew C. Charles, MD, FAHS
University of California, Los Angeles
Los Angeles, CA